Introduction
============

The rapid development of medical equipment to help physicians in their decision making has led to fundamental changes in management of patients throughout medical specialties. The implementation of new techniques in clinical practice is often based on the opportunity to assess pathological findings thought to be of importance, but randomised clinical trials assessing the added value of new techniques on patients' outcomes are often not undertaken before care of patients is changed.

The management of rheumatoid arthritis has improved greatly over the past decade with the introduction of biologic agents, tight control strategies, and early disease modifying anti-rheumatic drug treatment.[@ref1] [@ref2] [@ref3] [@ref4] [@ref5] [@ref6] [@ref7] [@ref8] [@ref9] With the improvement in rheumatoid arthritis care, remission has become an achievable goal for a large proportion of patients,[@ref10] [@ref11] [@ref12] [@ref13] but studies have shown that clinical remission does not necessarily exclude progression of joint damage.[@ref14] [@ref15] An increasing number of rheumatologists use ultrasound in the management of rheumatic diseases. Ultrasound can assess two aspects of synovitis---the morphology and quantity by grey scale and synovial vascularity by power Doppler---and it has been a promising tool for monitoring of disease activity in rheumatoid arthritis.[@ref16] [@ref17] [@ref18] Ultrasound has been shown to be more sensitive than clinical examination in detecting joint inflammation and to improve the certainty of a diagnosis of rheumatoid arthritis,[@ref19] [@ref20] [@ref21] [@ref22] and it may also be helpful in procedures such as aspiration of joint fluid and intra-articular corticosteroid injections.[@ref23] [@ref24] Joint inflammation visualised by ultrasound is present in a majority of rheumatoid arthritis patients in clinical remission, and several studies have shown that power Doppler activity is associated with radiographic progression and disease flare in these patients.[@ref19] [@ref25] [@ref26] [@ref27] [@ref28] [@ref29] [@ref30] The potential importance of ultrasound in the definition of rheumatoid arthritis remission and the monitoring of disease activity has led to interest in the concept of imaging remission---that is, abrogation of inflammation assessed by sensitive imaging techniques.[@ref31] [@ref32] [@ref33] [@ref34] [@ref35]

The ARCTIC (Aiming for Remission in rheumatoid arthritis: a randomised trial examining the benefit of ultrasound in a Clinical TIght Control regimen) study was designed to compare two tight control treatment strategies for early rheumatoid arthritis to assess whether incorporation of ultrasound information into treatment decisions as well as targeting therapy towards imaging remission would lead to improvement in a combined outcome of sustained clinical remission, absence of swollen joints, and inhibition of joint damage.

Methods
=======

Study design
------------

The ARCTIC trial was a 24 month randomised, open label, parallel group clinical strategy study conducted at 11 centres in Norway (four rheumatology departments at university hospitals, six regional/community hospitals, and one private practice) in compliance with the Declaration of Helsinki and the International Conference on Harmonization Guidelines for Good Clinical Practice. The study was conducted and analysed according to the protocol and the statistical analysis plan (see appendix).

Participants
------------

The main inclusion criteria were age 18-75 years, fulfilment of the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for rheumatoid arthritis,[@ref36] naivety to disease modifying anti-rheumatic drugs, time from first patient reported swollen joint less than two years, and indication for disease modifying drug treatment. Patients with abnormal kidney or liver function or major comorbidities were excluded (full inclusion and exclusion criteria in section 2 of the appendix). All patients provided written informed consent.

Randomisation and masking
-------------------------

Patients were randomised one to one to either an "ultrasound tight control" or a "conventional tight control" strategy. The site investigators enrolled patients, and randomisation was computer generated with block design, concealment of allocation by opaque sequentially numbered sealed envelopes (prepared by a contract research organisation, Smerud Medical Research, Oslo, Norway), and stratification for study centre and presence of anti-cyclic citrullinated peptide antibodies. Investigators and patients were aware of the allocated treatment group. The readers of the radiographs were masked for clinical information and strategy arm, and unblinded study personnel made clinical assessments including joint counts.

Assessments
-----------

Patients were assessed at 0, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 months. Patients in the ultrasound strategy arm were assessed by ultrasound at every visit, according to a scoring system of 32 joints with high intra-rater and inter-rater reliability.[@ref37] According to the scoring system, these 32 joints were scored semi-quantitatively as 0-3 for both grey scale and power Doppler: metacarpophalangeal joints 1-5, radiocarpal joint, intercarpal joint, distal radioulnar joint, elbow, knee, talocrural joint, and metatarsophalangeal joints 1-5 bilaterally, giving ranges from 0 to 192 for total ultrasound score and from 0 to 96 for grey scale and power Doppler ultrasound scores. The ultrasound assessments were performed with Siemens Antares or GE Logiq E9 ultrasound machines with linear probes (11.4/13.0 MHz). Power Doppler parameters were adjusted according to the device used (pulse repetition frequency 391/600 Hz; Doppler frequency 7.3/10.0 MHz).[@ref38] No changes in ultrasound settings were made during the study, and no software was upgraded. Patients in the conventional tight control arm were assessed by ultrasound yearly, but both the patient and the treating physician were blinded to the results, and the treating physicians did not have access privileges to ultrasound data in the electronic case report form. In the ultrasound strategy arm, the sonographer was also the treating physician, and patients were informed of the ultrasound results. All the sonographers participating in the study were experienced and underwent extensive training with both static and dynamic hands-on exercises to calibrate readers before the inclusion of the first patient and an ultrasound workshop to ensure that calibration was repeated annually during data collection. A published atlas with ultrasound images showing the range of scores of both power Doppler and grey scale synovitis in the assessed joints was available at all study centres for reference.[@ref37] Multicentre training and calibration exercises of clinical joint examinations took place before the start of the study and at annual investigator meetings during the conduct of the study. Examinations were performed according to the EULAR handbook of clinical assessments in rheumatoid arthritis.[@ref39]

Treatment strategies
--------------------

The ultrasound tight control strategy targeted ultrasound imaging remission, defined as no ultrasound power Doppler signal in any assessed joint, in combination with clinical remission, whereas the clinical tight control strategy was targeted towards clinical remission only. We based the choice of no ultrasound power Doppler signal in any assessed joint as the preferred ultrasound treatment target on available literature and extensive discussions with clinicians and researchers.[@ref29] Clinical remission was defined as Disease Activity Score (DAS) below 1.6 and no swollen joints. DAS (range 0-10, higher score indicating more disease activity) is a composite index of four variables: the number of swollen joints among 44 examined joints, the Ritchie Articular Index with a graded assessment 0-3 of the tenderness in 26 joint regions, the erythrocyte sedimentation rate, and the patient's global assessment on a visual analogue scale ranging from 0 to 100.[@ref40] The treatment in both arms was escalated according to the same algorithm, shown in figure 1[](#f1){ref-type="fig"} (more details in section 3 of the appendix). The initial treatment was methotrexate 15 mg/week increased to 20 mg/week by week five, in combination with seven weeks of prednisolone with tapering doses from 15 mg to zero. Further steps in the treatment algorithm included methotrexate 25 mg/week, triple synthetic disease modifying drug therapy (methotrexate, sulfasalazine, hydroxychloroquine) and biologic treatment according to guidelines (fig 1[](#f1){ref-type="fig"} and appendix table S1). In both arms, swollen joints were treated by intra-articular steroids; additionally, any joint with power Doppler signal in the ultrasound tight control arm should be injected. All injections in the ultrasound tight control arm were guided by ultrasound.

![**Fig 1** Protocol for escalation of disease modifying anti-rheumatic (DMARD) treatment. If patient responds or reaches target, current treatment is continued. \*In patients with high disease activity and risk factors for progressive joint destruction, rescue option is available which includes moving to step 5 (introduce first biologic). †This step requires signs of ongoing inflammatory activity. TNF=tumour necrosis factor](haae031902.f1_default){#f1}

The clinical decision to adjust therapy was based on level of and change in DAS.[@ref41] In the ultrasound arm, the physician should overrule the DAS based decision and proceed to the next treatment regimen if indicated by the ultrasound score. We applied a data driven approach to derive cut-off values for the ultrasound change score in a previously collected dataset using the same ultrasound score, by assessing the magnitude of changes in ultrasound score corresponding to established cut-off values for changes in DAS. The chosen cut-off values of 10% and 20% change in ultrasound scores corresponded to DAS changes of more than 0.6 and 1.2, respectively. If the patient did not respond adequately (appendix table S2), the physician immediately adjusted the therapy by proceeding to the next step in the treatment algorithm. Current therapy was continued if the treatment response was satisfactory. Study personnel entered information on DAS values at the current and previous visit, as well as the ultrasound score at both visits if applicable, into a web page that automatically applied the treatment decisions rules in the appropriate study arm (appendix table S2), and the treating physician was presented with the outcome of the response assessment and whether to escalate treatment.

Outcomes
--------

The predefined primary efficacy endpoint was the proportion of patients meeting the following criteria: sustained clinical remission, defined as DAS less than 1.6 at 16, 20, and 24 months; no swollen joints at 16, 20, and 24 months; and no radiographic progression (\<0.5 units change in van der Heijde modified Sharp score) between 16 and 24 months.

Radiographs of hands, wrists, and feet were obtained at 0, 3, 6, 12, 16, and 24 months. Two trained readers, blinded for clinical data and treatment strategy, scored radiographs independently in chronological order according to the van der Heijde modified Sharp score (subscores for erosions (0-280) and joint space narrowing (0-168), total range 0-448, higher scores indicating more joint damage). We used the average of the two readings for all analyses.

Secondary endpoints included DAS remission, Simplified Disease Activity Index remission (this index ranges from 0 to 86, with higher scores indicating more disease activity; remission is defined as an index ≤3.3), ACR core set outcome variables (assessment of tender and swollen joints, pain, patient and investigator global assessment of disease activity, erythrocyte sedimentation rate, and C reactive protein), and fatigue visual analogue scale. We assessed physical function by the Patient-Reported Outcomes Measurement Information 20 item short form (range 20-100, translated to a T score with a mean of 50 and a standard deviation of 10). EuroQol-5 dimensions was assessed with values based on UK preference weights with range from 1 (best possible health), through 0 (death) to −0.59 (worse than death). We included the Rheumatoid Arthritis Impact of Disease score, a patient derived weighted score to assess seven domains of the impact of rheumatoid arthritis (range 0-10, where higher values indicate worse status). Additionally, we assessed changes from baseline in DAS and van der Heijde modified Sharp score, the proportion of patients with radiographic progression according to different cut-off values, and EULAR response rates (details in statistical analysis plan in appendix). A complete list of secondary outcomes is provided in the appendix. We have not reported a subset of the pre-specified outcomes, either because of feasibility problems or because the methodology and interpretation of results would be beyond the scope of this paper (magnetic resonance imaging outcomes, work productivity and activity impairment outcomes, dual energy *x* ray absorptiometry outcomes, and outcomes from the Medical Outcomes Study Short Form 36 item). The results of these analyses will be published in full in more specialised journals and provided in the ClinicalTrials.gov database (NCT01205854). We evaluated safety by assessment of clinical and laboratory adverse events and coded serious adverse events according to the Medical Dictionary for Regulatory Activities (MedDRA, v17.0).

Patient involvement
-------------------

No patients were involved in the development of the research question or the outcome measures, nor were they involved in the design of the study, the recruitment of study participants and the conduct of the study. The main results from the study will be disseminated to study participants in a study newsletter.

Statistical analyses
--------------------

We determined the sample size on the basis of an assumed treatment difference of 20% (45% *v* 65%) in the proportion of patients reaching the primary endpoint, yielding 98 patients in each group to reach 80% power. We aimed to include 240 patients to compensate for attrition. Efficacy and safety analyses included data from all randomised patients who started the allocated intervention by attending at least one regular visit after randomisation (the full analyses set).

We used unadjusted logistic regression to assess the primary endpoint and other categorical endpoints. We did not adjust the analyses for the stratification factors centre and presence of anti-cyclic citrullinated peptide antibodies owing to low cell frequencies. If the primary endpoint components or other categorical values were missing at month 24, we imputed values with worst outcome. We imputed missing values before month 24 with the last known value. We calculated estimates of risk difference from the logistic regression parameters by using the delta method to provide confidence intervals. We used median regression with 10 000 bootstrap replications to estimate the difference in median radiographic change scores; we used linear intrapolation and extrapolation to impute missing values. To analyse other continuous change variables, we used analysis of covariance adjusted for baseline value in addition to study centre and presence of anti-cyclic citrullinated peptide antibodies. We used least square means to calculate estimates of treatment difference. We handled missing values by using multiple imputations with 10 imputations drawn from the observed distribution, using the Markov chain Monte Carlo method. The statistical significance level was set at 0.05, and all significance tests were two sided. Secondary analyses were not adjusted for multiple testing. Further statistical details are described in the statistical analyses plan and appendix section 4. A data monitoring committee was not established for this trial. We used Stata Statistical Software version 14 for all statistical analyses.

Results
=======

Patient disposition and baseline characteristics
------------------------------------------------

Between 30 September 2010 and 30 April 2013, 238 patients with early rheumatoid arthritis were included in the ARCTIC trial (fig 2[](#f2){ref-type="fig"}). One hundred and eighteen patients received the allocated ultrasound tight control treatment strategy and 112 patients received the conventional tight control strategy and were included in the primary analysis (fig 2[](#f2){ref-type="fig"}). Of the included patients, 104 completed the ultrasound tight control arm and 100 completed the conventional tight control arm. The frequencies and reasons for not receiving allocated treatment strategy and for discontinuation during the study were similar in the two arms. The two arms were well balanced overall with regard to baseline characteristics, but more women were randomised to the ultrasound arm (71% *v* 51%) (table 1[](#tbl1){ref-type="table"}). The difference in sex distribution could not be attributed to a specific study centre (appendix table S5).

![**Fig 2** Trial profile. DMARD=disease modifying anti-rheumatic drug; RA=rheumatoid arthritis](haae031902.f2_default){#f2}

###### 

Baseline characteristics. Values are means (SDs) unless stated otherwise

  Characteristics                                                    Ultrasound tight control (n=118)   Conventional tight control (n=112)
  ------------------------------------------------------------------ ---------------------------------- ------------------------------------
  Age, years                                                         50.6 (13.3)                        52.3 (14.1)
  No (%) women                                                       84 (71)                            57 (51)
  Body mass index                                                    25.6 (4.4)                         26.1 (4.7)
  No (%) current smoker                                              23 (19)                            32 (29)
  Time since patient reported first swollen joint, months            6.8 (5.2)                          7.4 (5.6)
  No (%) anti-citrullinated peptide antibody positive                93 (79)                            93 (83)
  No (%) rheumatoid factor positive                                  78 (66)                            86 (77)
  Disease Activity Score                                             3.51 (1.19)                        3.40 (1.16)
  Simplified Disease Activity Index                                  25.5 (12.9)                        24.4 (13.3)
  Disease Activity Score based on 28 joints                          4.42 (1.19)                        4.39 (1.20)
  Patient's global assessment of disease activity, mm (0-100)        51.9 (24.7)                        47.5 (23.9)
  Investigator's global assessment of disease activity, mm (0-100)   40.9 (20.1)                        40.3 (21.2)
  Swollen joint count (0-44)                                         10.9 (7.2)                         10.2 (7.8)
  Tender joint count (Ritchie Articular Index, 0-78)                 9.2 (7.9)                          8.4 (6.7)
  Erythrocyte sedimentation rate, mm/hr (1-140)                      23.2 (18.3)                        25.8 (18.9)
  C reactive protein, mg/L                                           14.5 (20.1)                        16.6 (22.39
  PROMIS Physical Function (12.1-62.5)                               38.9 (9.2)                         39.2 (8.1)
  Median (IQR) EuroQol-5 dimensions (−0.59-1.0)                      0.66 (0.16-0.73)                   0.66 (0.47-0.73)
  Fatigue visual analogue scale, mm (0-100)                          43.7 (28.4)                        37.0 (28.6)
  Pain visual analogue scale, mm (0-100)                             48.8 (23.9)                        46.8 (24.3)
  Median (IQR) van der Heijde modified Sharp score (0-448)           3.8 (1.5-7.5)                      5.0 (2.0-10.3)
   Median (IQR) erosion score                                        2.5 (1.0-4.0)                      3.5 (1.5-5.8)
   Median (IQR) joint space narrowing score                          1.0 (0.0-3.0)                      1.0 (0.0-4.5)
  Median (IQR) ultrasound total score (0-192)                        24 (16-37)                         27 (14-45)
   Median (IQR) ultrasound grey scale score                          17 (10-24)                         19 (10-31)
   Median (IQR) ultrasound power Doppler                             7 (3-13)                           7 (2-15)
   No (%) power Doppler signal in any joint                          110 (93.2)                         97 (86.6)

IQR=interquartile range; PROMIS=Patient-reported Outcomes Measurement Information Score Short Form v1.0 -- Physical Function 20a (reported as T scores).

Clinical outcomes
-----------------

The ultrasound tight control strategy was not superior to the conventional tight control strategy with regards to the primary outcome (sustained remission, absence of radiographic damage, and absence of swollen joints between month 16 and 24 of the study). Twenty six (22%) patients in the ultrasound tight control group and 21 (19%) patients in the conventional tight control group reached the primary outcome, with a difference between the groups of 3.3% (95% confidence interval −7.1 to 13.7; P=0.54) and a risk ratio of 1.18 (95% confidence interval 0.57 to 1.78). We found no difference between the groups for any of the three components of the primary outcome (table 2[](#tbl2){ref-type="table"}).

###### 

Primary and secondary outcomes. Values are numbers (percentages) unless stated otherwise

                                                                                            Ultrasound tight control (n=118)   Conventional tight control (n=112)   Difference (95% CI)     P value
  ----------------------------------------------------------------------------------------- ---------------------------------- ------------------------------------ ----------------------- ---------
  **Primary endpoint**                                                                                                                                                                      
  Clinical remission, no swollen joints, and non-progression of radiographic joint damage   26 (22)                            21 (19)                              3.3 (−7.1 to 13.7)      0.54
  **Components of primary endpoint**                                                                                                                                                        
  No swollen joints at 16, 20, and 24 months\*                                              62 (53)                            61 (54)                              −1.9 (−14.8 to 11.0)    0.77
  Disease Activity Score remission at 16, 20, and 24 months\*                               64 (54)                            58 (52)                              2.5 (−10.4 to 15.4)     0.71
  No radiographic progression between 16 and 24 months\*                                    49 (42)                            39 (35)                              6.7 (−5.8 to 19.2)      0.29
  **Measures of disease activity, physical function, and quality of life**                                                                                                                  
  Mean (SD) change in Disease Activity Score:                                                                                                                                               
   At 12 months                                                                             −2.2 (1.1)                         −2.1 (1.2)                           0.1 (−0.1 to 0.3)       0.26
   At 24 months                                                                             −2.3 (1.2)                         −2.0 (1.2)                           −0.1 (−0.3 to 0.1)      0.49
  Disease Activity Score remission (Disease Activity Score \<1.6)†:                                                                                                                         
   At 12 months                                                                             76 (64)                            81 (72)                              −7.9 (−19.9 to 4.1)     0.20
   At 24 months                                                                             80 (68)                            75 (67)                              0.8 (−11.3 to 13.0)     0.89
  Mean (SD) change in erythrocyte sedimentation rate, mm/hr:                                                                                                                                
   At 12 months‡                                                                            −11.6 (16.5)                       −14.9 (18.6)                         0.9 (−1.2 to 3.1)       0.39
   At 24 months‡                                                                            −13.0 (16.8)                       −13.7 (17.7)                         −1.1 (-3.3 to 1.0)      0.30
  Mean (SD) change in C reactive protein, mg/L:                                                                                                                                             
   At 12 months‡                                                                            −10.1 (19.6)                       −11.7 (21.6)                         0 (−1.1 to 1.0)         0.92
   At 24 months‡                                                                            −11.0 (19.9)                       −11.3 (21.9)                         −1.0 (−2.3 to 0.2)      0.11
  Mean (SD) change in investigator's global assessment:                                                                                                                                     
   At 12 months‡                                                                            −34.8 (19.9)                       −29.9 (21.2)                         −1.3 (−3.3 to 0.7)      0.19
   At 24 months‡                                                                            −33.0 (21.6)                       −28.0 (23.2)                         −2.6 (−5.5 to 0.4)      0.09
  Mean (SD) change in patient's global assessment:                                                                                                                                          
   At 12 months‡                                                                            −35.1 (25.3)                       −29.2 (28.8)                         −1.3 (−6.3 to 3.7)      0.61
   At 24 months‡                                                                            −35.9 (25.9)                       −29.7 (28.1)                         −0.75 (−6.0 to 4.5)     0.78
  Mean (SD) change in Disease Activity Score 28 joints:                                                                                                                                     
   At 12 months‡                                                                            −2.4 (1.3)                         −2.4 (1.4)                           0.1 (−0.1 to 0.4)       0.29
   At 24 months‡                                                                            −2.5 (1.3)                         −2.2 (1.3)                           −0.2 (−0.4 to 0.1)      0.23
  Mean (SD) change in Simplified Disease Activity Index:                                                                                                                                    
   At 12 months‡                                                                            −21.3 (12.6)                       −18.9 (12.8)                         −0.1 (−1.3 to 1.0)      0.83
   At 24 months‡                                                                            −20.8 (13.5)                       −18.3 (13.1)                         −0.5 (−2.1 to 1.1)      0.56
  Simplified Disease Activity Index remission (Simplified Disease Activity Index\<3.3)†:                                                                                                    
   At 12 months                                                                             67 (57)                            61 (54)                              2.3 (−10.5 to 15.2)     0.72
   At 24 months                                                                             71 (60)                            56 (50)                              10.2 (−2.6 to 23.0)     0.12
  ACR-EULAR boolean remission†:                                                                                                                                                             
   At 12 months                                                                             50 (42)                            47 (42)                              0.4 (−12.4 to 13.2)     0.95
   At 24 months                                                                             57 (48)                            55 (49)                              −0.8 (−12.7 to 12.1)    0.90
  EULAR good/moderate response†:                                                                                                                                                            
   At 12 months                                                                             97 (82)                            93 (83)                              −0.8 (−10.6 to 9.0)     0.87
   At 24 months                                                                             98 (83)                            90 (80)                              2.7 (−7.3 to 12.7)      0.60
  No tender joints†‡:                                                                                                                                                                       
   At 12 months                                                                             57 (48)                            64 (57)                              −8.8 (−21.7 to 4.0)     0.18
   At 24 months                                                                             67 (57)                            60 (54)                              3.2 (-9.6 to 16.1)      0.63
  No swollen joints†‡:                                                                                                                                                                      
   At 12 months                                                                             87 (74)                            78 (70)                              4.1 (−7.6 to 15.7)      0.49
   At 24 months                                                                             84 (71)                            75 (67)                              4.2 (−7.7 to 16.2)      0.49
  Mean (SD) change in PROMIS Physical Function:                                                                                                                                             
   At 12 months                                                                             11.6 (9.1)                         11.6 (8.6)                           −0.3 (−2.4 to 1.8)      0.80
   At 24 months                                                                             13.0 (9.5)                         11.0 (9.6)                           1.28 (−1.1 to 3.6)      0.28
  Mean (SD) change in EQ-5D:                                                                                                                                                                
   At 12 months‡                                                                            0.28 (0.28)                        0.25 (0.29)                          0 (−0.05 to 0.05)       0.95
   At 24 months                                                                             0.30 (0.28)                        0.26 (0.28)                          −0.01 (−0.06 to 0.05)   0.84
  Mean (SD) change in Rheumatoid Arthritis Impact of Disease score:                                                                                                                         
   At 12 months                                                                             −2.6 (2.0)                         −2.4 (2.3)                           −0.08 (−0.51 to 0.35)   0.71
   At 24 months                                                                             −2.8 (2.1)                         −2.5 (2.3)                           −0.06 (−0.49 to 0.38)   0.79
  Mean (SD) change in fatigue visual analogue scale:                                                                                                                                        
   At 12 months‡                                                                            −20.0 (31.4)                       −15.6 (28.5)                         1.0 (−4.9 to 6.8)       0.75
   At 24 months‡                                                                            −20.8 (32.7)                       −14.8 (28.7)                         1.7 (−4.8 to 8.2)       0.61
  Mean (SD) change in pain visual analogue scale:                                                                                                                                           
   At 12 months‡                                                                            −32.5 (24.8)                       −29.2 (28.1)                         −0.82 (−6.0 to 4.3)     0.75
   At 24 months‡                                                                            −31.9 (26.7)                       −29.1 (25.0)                         0.03 (−5.1 to 5.2)      0.99
  **Radiographic joint damage**                                                                                                                                                             
  Median (IQR) changes in modified Sharp score:                                                                                                                                             
   At 12 months                                                                             0.5 (0-1.0)                        0.5 (0-1.5)                          −0.28 (−0.60 to 0.04)   0.08
   At 24 months                                                                             1.0 (0-2.5)                        1.5 (0.5-3.0)                        −0.45 (−0.90 to 0)      0.05
  Median (IQR) change in erosion score:                                                                                                                                                     
   At 12 months                                                                             0 (0-1.0)                          0.5 (0-1.0)                          −0.35 (−0.70 to 0)      0.05
   At 24 months                                                                             0.5 (0-1.5)                        1.0 (0.5-2.0)                        −0.38 (−0.76 to 0.01)   0.06
  Median (IQR) change in joint space narrowing score:                                                                                                                                       
   At 12 months                                                                             0 (0-0.5)                          0 (0-0)                              0 (−0.03 to 0.03)       \>0.99
   At 24 months                                                                             0 (0-0.5)                          0 (0.0-0.5)                          0 (−0.05 to 0.05)       \>0.99
  Progression, modified Sharp score ≥1.0 units/year†                                        43 (36)                            53 (47)                              −10.9 (−23.6 to 1.8)    0.09
  **Ultrasound outcomes**                                                                                                                                                                   
  Mean (SD) change in ultrasound total score:                                                                                                                                               
   At 12 months                                                                             −25.0 (18.3)                       −23.7 (23.4)                         −3.7 (−5.8 to -1.7)     \<0.001
   At 24 months                                                                             −25.5 (18.3)                       −26.7 (26.1)                         −2.2 (−4.0 to -0.42)    0.02
  Mean (SD) change in ultrasound grey scale score:                                                                                                                                          
   At 12 months                                                                             −15.9 (11.6)                       −15.0 (13.9)                         −2.7 (−4.3 to -1.2)     0.001
   At 24 months                                                                             −16.5 (11.6)                       −17.1 (15.6)                         −1.6 (−2.9 to -0.28)    0.02
  Mean (SD) change in ultrasound power Doppler:                                                                                                                                             
   At 12 months                                                                             -9.2 (8.2)                         −8.8 (10.5)                          −1.0 (−1.7 to -0.29)    0.007
   At 24 months                                                                             -9.0 (8.1)                         −9.6 (11.5)                          −0.61 (−1.3 to 0.04)    0.06
  No power Doppler signal in any joint†:                                                                                                                                                    
   At 12 months                                                                             94 (80)                            60 (54)                              26.1 (14.3 to 37.8)     \<0.001
   At 24 months                                                                             89 (75)                            69 (62)                              13.8 (1.9 to 25.7)      0.02
  **Drug treatment**‡                                                                                                                                                                       
  Disease modifying anti-rheumatic drug regimen at 24 months:                                                                                                                               
   Methotrexate monotherapy                                                                 63 (53)                            80 (71)                              −18.0 (−30.3 to -5.8)   0.004
   Methotrexate/sulfasalazine/hydroxychloroquine combination                                21 (18)                            13 (12)                              6.2 (−2.9 to 15.3)      0.18
   Biologic treatment                                                                       34 (29)                            19 (17)                              11.8 (1.1 to 22.6)      0.03
    First biologic                                                                          27 (23)                            10 (9)                               14.0 (4.7 to 23.2)      0.003
    Second biologic                                                                         5 (4)                              9 (8)                                −3.8 (v10.0 to 2.4)     0.23
    Third biologic                                                                          2 (2)                              0 (0)                                NE                      0.50
  Mean (SD) methotrexate dose at 24 months, mg                                              20.4 (5.0)                         21.1 (4.5)                           −0.7 (−2.1 to 0.6)      0.28
  Median (IQR) total prednisolone dose, mg§                                                 570 (420-890)                      634 (468-844)                        −2.5 (−71.5 to 66.5)    0.94
  Any NSAID use over 24 months                                                              55 (47)                            52 (46)                              0 (−0.12 to 0.13)       0.98
  Any intra-articular injections                                                            103 (87)                           86 (77)                              10.5 (0.6 to 20.4)      0.04
  Mean (SD) No of intra-articular injections                                                6.5 (6.0)                          4.9 (5.9)                            1.7 (0.2 to 3.2)        0.03
  Mean (SD) total triamcinolone hexacetonide dose, mg§                                      94 (88)                            69 (129)                             25 (−4 to 54)           0.09

ACR=American College of Rheumatology; EQ-5D=EuroQol-5 dimensions; EULAR=European League Against Rheumatism; NE=not estimable (P value based on Fischer's exact test for third biologic); NSAID=non-steroidal anti-inflammatory drug; PROMIS=Patient-reported Outcomes Measurement Information Score Short Form v1.0 -- Physical Function 20a (reported as T scores).

\*Missing data before 24 months imputed using last observation carried forward; missing data at 24 months imputed using worst outcome.

†Missing data were imputed using worst outcome imputation.

‡Outcomes not listed in the ClinicalTrials.gov registry on 20 September 2010 (before patient enrolment), but described in trial protocol and/or statistical analyses plan before database lock and analyses (see appendix).

§Cumulative dose per patient.

At 24 months, 68% and 67% of the patients in the two arms were in DAS remission (table 2[](#tbl2){ref-type="table"}). We found no significant differences in remission rates at 12 or 24 months for either of the remission criteria sets analysed. DAS scores, DAS remission rates, Simplified Disease Activity Index remission rates, and ACR/EULAR boolean remission rates were comparable in the two study arms during the 24 month study period (fig 3[](#f3){ref-type="fig"}). More than 80% of patients in both arms showed EULAR good or moderate response at 12 months, and this was sustained throughout the study. The patients' and assessors' evaluation of the disease activity showed substantial improvement compared with baseline, with similar results at 12 and 24 months. Patients in both groups reported similar levels of improvement in physical function. More patients in the ultrasound tight control arm (29%) than in the conventional tight control arm (17%) received biologic treatment at the end of the study, and fewer patients received methotrexate monotherapy (53% *v* 71%). In the ultrasound tight control arm, 167 treatment escalations and 770 intra-articular corticosteroid injections occurred, compared with 124 treatment escalations and 548 intra-articular corticosteroid injections in the conventional tight control arm.

![**Fig 3** Top left: Disease Activity Score (DAS) over 24 months; least square mean estimates of DAS at all visits derived from mixed effects longitudinal model adjusted for baseline value and stratification factors. Top right: proportion of patients who achieved DAS remission over 24 months derived from logistic regression model. Bottom left: proportion of patients who achieved Simplified Disease Activity Index (SDAI) remission over 24 months derived from logistic regression model. Bottom right: proportion of patients who achieved American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) boolean remission over 24 months from logistic regression model. Bars indicate 95% confidence limits](haae031902.f3_default){#f3}

Radiographic outcomes
---------------------

The median change in total van der Heijde modified Sharp score over 24 months was low, with no statistically significant differences between the two strategies. We observed a borderline statistically significant difference in the 24 month change in radiographic joint damage between the groups, favouring the ultrasound tight control strategy (table 2[](#tbl2){ref-type="table"}), and this is visualised in the cumulative probability plot (fig 4[](#f4){ref-type="fig"}). The proportion of patients with radiographic progression did not differ between the two strategy arms (table 2[](#tbl2){ref-type="table"}), and we found similar results in sensitivity analyses with different cut-off values for yearly progression (≥0.5 units, ≥2.0 units, ≥5 units).

![**Fig 4** Cumulative probability plot of change between baseline and 24 months in van der Heijde modified Sharp score](haae031902.f4_default){#f4}

Sensitivity analyses
--------------------

In sensitivity analyses, we analysed the primary endpoint, components of the primary endpoint, and the 24 month change in radiographic damage with adjustment for sex (appendix table S3), with similar results as for the main analysis. We also found similar results in analyses of the primary endpoint with imputation of best outcome instead of worst outcome (data not shown). We also analysed the same variables in the completer dataset consisting of 204 patients (appendix table S4). In these analyses, we found a significant difference in radiographic damage over 24 months, with a difference in change of van der Heijde Sharp score of 0.45 units (95% confidence interval −0.86 to −0.39; P=0.03) favouring the ultrasound tight control group.

Adverse events
--------------

The overall frequency of adverse events and serious adverse events was similar in the two arms (table 3[](#tbl3){ref-type="table"}). Thirteen (6%) patients had serious adverse events, of whom five (2%) had serious infections (table 3[](#tbl3){ref-type="table"}, appendix table S6). Five cases of cancer were reported: two (follicle centre lymphoma, liver metastases) in the ultrasound tight control arm and three (basal cell carcinoma, breast cancer, squamous cell carcinoma) in the conventional tight control arm (appendix section 5). One patient in the ultrasound tight control arm died from *Pneumocystis jirovecii* pneumonia (appendix section 6).

###### 

Safety data from month 0 to 24. Values are numbers (percentages)

  ----------------------------------------------------------------------------------------------------------
   Outcome                                          Ultrasound tight control (n=118)   Conventional tight\
                                                                                       control (n=112)
  ------------------------------------------------- ---------------------------------- ---------------------
  Adverse events                                    417                                455

  Patients with adverse events                      96 (81)                            91 (81)

  Patients with serious adverse events              6 (5)                              7 (6)

  Patients with serious infection                   3 (3)\*                            2 (2)†

  Discontinuation from study due to adverse event   7 (6)                              5 (4)

  Patients with cancer                              2 (2)‡                             3 (3)§

  Death                                             1 (1)¶                             0
  ----------------------------------------------------------------------------------------------------------

\**Pneumocystis jirovecii* pneumonia, pneumonia, and bacterial abscess.

†Abscess and localised infection.

‡Follicle centre lymphoma and metastases to liver.

§Basal cell carcinoma, breast cancer, and squamous cell carcinoma.

¶Patient died from *Pneumocystis jirovecii* pneumonia.

Discussion
==========

In this study, we assessed the benefit of adding ultrasound information to the treatment decisions and treatment target in early rheumatoid arthritis. The study was designed on the basis of the increasing application of ultrasound in clinical practice, as well as several studies showing that ultrasound examinations improve assessment of synovitis and prediction of important patient outcomes.[@ref19] Our study found no additional effect of an ultrasound tight control strategy compared with a conventional tight control strategy for the primary outcome of the study or for other measures of disease activity, joint damage, and physical function.

Strengths and limitations of study
----------------------------------

The study has limitations as well as strengths. This was an open study, and two components of the primary endpoint, the tender and swollen joint counts, were not blinded. This leaves a potential for bias in treatment decisions based on these parameters. Although remission rates were excellent, fewer patients than expected in the power calculations reached the strict composite primary outcome. In our sample size estimations, we aimed for 80% power to detect a 20% difference between the interventions (see protocol). If the study was to be repeated, the power to detect a 20% difference in the primary endpoint from 19% in the control group would have been 89%, showing that the completed trial was not underpowered to detect a clinically important difference. This can also be deduced from the results presented in this manuscript. The estimated treatment difference of the primary endpoint was 3.3% with a 95% confidence interval of −7.1 to 13.7. The confidence limits of the primary efficacy outcome are completely within the ±20% margin, excluding a clinically significant effect of the intervention (appendix section 7). Sensitivity analyses in the completer population and analyses in the full analyses set with imputation of best outcome instead of worst outcome resulted in similar results, supporting our conclusion. A pilot study showed good intra-reader and inter-reader reliability for the ultrasound scoring system,[@ref37] but no consensus has been reached on the optimal scoring system for ultrasound in rheumatoid arthritis.[@ref18] Our findings are strengthened by both strategies adhering to international recommendations,[@ref10] [@ref13] and by the fact that the primary endpoint comprised sustained clinical remission and halt of radiographic progression, thus capturing the most important aspects of rheumatoid arthritis.[@ref4] Two trained and blinded readers at a central facility read radiographs with known chronological order, to optimise sensitivity to change.[@ref42] The inclusion criteria stated that the patients should have a clinical indication for disease modifying anti-rheumatic drug therapy, as well as a diagnosis of rheumatoid arthritis and fulfilment of the 2010 ACR/EULAR classification criteria. We imposed no formal entry criteria regarding the level of DAS. At baseline, the mean DAS was in the upper range of moderate. We aimed to include a study population capturing a broad range of rheumatoid arthritis disease activity, not a subset with high disease activity, as is often the case in studies of new drugs. We believe this heterogeneity to be a strength of the study, as it reflects real life practice.

Comparison with other studies
-----------------------------

The introduction of biologic therapies in combination with aggressive treatment strategies has led to levels of disease control previously thought impossible in rheumatoid arthritis, and remission has become a realistic goal of therapy.[@ref3] [@ref4] [@ref9] [@ref10] [@ref11] [@ref12] [@ref13] [@ref15] Remission rates in both study arms of this trial were excellent compared with other trials of strategy in early rheumatoid arthritis, with minimal radiographic progression.[@ref1] [@ref43] [@ref44] [@ref45] [@ref46] Our results showcase the power of a treatment approach targeting deep clinical remission, follow-up with tight control, and starting treatment with methotrexate and prednisolone, combined with intra-articular injections in swollen joints. After 24 months, more than 70% of patients in the conventional arm were still on methotrexate monotherapy and only 17% needed a biologic agent. In an ideal setting, remission in rheumatoid arthritis should represent absence of inflammation and no progression of joint damage, but current clinical remission criteria do not include imaging assessments. A key question has been whether treatment of subclinical inflammation would improve long term outcomes or whether this will lead to overtreatment.[@ref19] [@ref31] [@ref32] [@ref35] We are aware of one other trial (NCT00920478) designed to assess the value of ultrasound in rheumatoid arthritis. The clinical target of that study was low disease activity and not remission, which is the preferred target in current treatment recommendations.[@ref11] [@ref13] Results from this trial indicate similar clinical and radiographic outcomes in both study arms.[@ref47]

Possible explanations and implications for clinicians
-----------------------------------------------------

The outcome of the study is to a certain degree surprising, in that a growing body of evidence suggested that subclinical inflammation, especially power Doppler activity, was associated with radiographic progression and flares.[@ref19] [@ref25] [@ref26] [@ref28] [@ref29] [@ref31] However, a recent study showed that radiographic progression was rare in joints with subclinical inflammation.[@ref48] The ultrasound strategy led to additional changes in disease modifying drug therapy, with fewer patients remaining on methotrexate monotherapy and more patients receiving biologic treatment, as well as a higher number of intra-articular corticosteroid injections. Adherence of patients and physicians to a pre-specified treatment protocol targeting remission can be challenging, and in several clinical situations rheumatologists may be reluctant to base treatment decisions solely on an algorithm rather than integrating all available information. A recent report from the BeST study evaluated rheumatologists' adherence to a treat to target strategy steered by DAS, and average protocol adherence was 79%.[@ref49] In our trial, we found that 19% of treatment changes deviated from the decision rules of the treatment algorithm. The result of each ultrasound joint assessment in the ultrasound tight control arm was communicated to the patient, and despite the extra time and effort required, most patients appreciated the opportunity to directly observe the level of inflammation inside the joints. This may contribute to increased adherence of patients to therapy, in that ongoing inflammation would improve patients' motivation to escalate treatment and resolution of inflammation might reassure the patient that the current therapy was effective.

Despite the more aggressive treatment in the ultrasound tight control group, inflammation assessed by ultrasound was significantly suppressed in both study arms, with most patients having no power Doppler activity in any joint after two years (appendix figure S1). A possible explanation may be that isolated subclinical inflammation in the absence of clinically detectable disease activity has minimal clinical importance, making direct visualisation of power Doppler activity unnecessary. We found a trend towards a difference in progression of joint damage, and we do not know whether a longer follow-up period would have shown a benefit of the ultrasound strategy. However, only a very subtle difference existed in the total modified Sharp score in the progression between the groups. In a study of patients with early rheumatoid arthritis who were followed over 10 years, a longitudinal association between total modified Sharp scores and functional outcome assessed by Health Assessment Questionnaire was found, and an increase of 10 units in the radiographic score was associated with a 0.03 unit increase (worsening) in Health Assessment Questionnaire score, which has a total range of 0-3 units.[@ref50] Thus, the observed difference of 0.45 modified Sharp score units over 24 months in our study is not clinically meaningful. The difference is present only in the erosion score and not in the joint space narrowing score, which has been found to be more strongly associated with irreversible loss of function than is erosive damage.[@ref51] The observed trend in the erosive score may be due to more frequent initiation of biologic drugs in the ultrasound tight control group, which is known to inhibit radiographic progression independently of disease activity.[@ref4]

Implications for policy makers
------------------------------

New drugs commonly undergo health economic evaluations before they are funded through national healthcare systems or private medical insurance, whereas such evaluations are less strictly imposed for new imaging modalities and other medical techniques before implementation into clinical care. Although we did not aim to analyse cost effectiveness data, the lack of gain in benefits and the increased costs, time consumption, and use of biologic drugs associated with the ultrasound tight control regimen would yield negative cost-benefit ratios.

Conclusions and future research
-------------------------------

The ARCTIC study highlights the importance of conducting randomised controlled trials to evaluate not only drugs but also new technologies or new treatment strategies. The implementation and systematic use of ultrasound in the follow-up of patients with early rheumatoid arthritis treated with an aggressive tight control strategy is not justified on basis of the results of the ARCTIC trial, and the result should be reflected in future recommendations and guidelines for managing patients with rheumatoid arthritis. Ultrasound may have an important role in the diagnosis of rheumatoid arthritis and in procedures such as intra-articular injections. Future studies should focus on the potential benefit of ultrasound in these areas, as well as the possible role of ultrasound in evaluating disease activity and tailoring treatment in patients with established rheumatoid arthritis.

### What is already known on this topic

1.  Clinical remission has become an achievable goal for a large proportion of patients with rheumatoid arthritis and is a defined target in treatment recommendations

2.  Several observational studies have shown that inflammation is present in rheumatoid arthritis patients who are in clinical remission

3.  Subclinical inflammation as assessed by sensitive imaging modalities is associated with structural progression and flare of disease activity

### What this study adds

1.  Adding ultrasound information into strategic treatment decisions and targeting therapy towards imaging remission (abrogation of inflammation as visualised by ultrasound) in rheumatoid arthritis did not lead to improved outcomes

2.  The application of ultrasound imaging remission as a treatment target in rheumatoid arthritis may lead to overtreatment and inefficient use of healthcare resources

3.  The ARCTIC study highlights the importance of conducting randomised controlled trials to evaluate not only drugs but also new imaging technologies or new treatment strategies
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Click here for additional data file.
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